Emphysematous Cholecystitis Secondary to Fusobacterium nucleatum

Fusobacterium nucleatum may be implicated in cases of emphysematous cholecystitis (EC) and carries a high mortality risk, especially in individuals with heart disease, renal insufficiency, and underlying malignancy. Fusobacterium infections are rarely detected in the setting of cholecystitis possibly due to the difficulty with properly culturing the bacteria. We describe a case of a patient with EC in whom blood cultures were positive for growth of F. nucleatum in one of two samples. The patient was treated with empiric antibiotic therapy consisting of metronidazole and cefepime. In patients with EC and negative cultures, it is possible that they may have an undetected infection with fusobacteria, which carries a high mortality risk. As such, clinicians should maintain a high degree of suspicion of obligate anaerobic infection in patients who have negative blood culture for growth in the setting of EC and consider continuation of adequate antimicrobial coverage.

[1]  E. Chan,et al.  The Link between Fusobacteria and Colon Cancer: a Fulminant Example and Review of the Evidence , 2020, Immune network.

[2]  Rasha E. Buhumaid,et al.  Point-of-care Ultrasound Diagnosis of Emphysematous Cholecystitis , 2020, Clinical practice and cases in emergency medicine.

[3]  Magnus Nordahl,et al.  Bacteria and fungi in acute cholecystitis. A prospective study comparing next generation sequencing to culture. , 2020, The Journal of infection.

[4]  Andrés Rey,et al.  Recuperación de bacterias aerobias y anaerobias de pacientes con apendicitis aguda mediante botellas de hemocultivo , 2019, Biomedica : revista del Instituto Nacional de Salud.

[5]  K. Mhamdi,et al.  Emphysematous Cholecystitis. , 2019, The New England journal of medicine.

[6]  S. Ali,et al.  Implication of Fusobacterium necrophorum in recurrence of peritonsillar abscess , 2018, The Laryngoscope.

[7]  D. Gouma,et al.  Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis , 2018, Journal of hepato-biliary-pancreatic sciences.

[8]  S. Diamantis,et al.  Detection of Fusobacterium nucleatum in culture-negative brain abscess by broad-spectrum bacterial 16S rRNA Gene PCR , 2017, IDCases.

[9]  M. Safwan,et al.  Emphysematous Cholecystitis , 2016 .

[10]  E. Denes,et al.  Fusobacterium nucleatum infections: clinical spectrum and bacteriological features of 78 cases , 2016, Infection.

[11]  M. Tsai,et al.  Emphysematous cholecystitis , 2016, Ci ji yi xue za zhi = Tzu-chi medical journal.

[12]  Krutika Kuppalli,et al.  Lemierre's syndrome due to Fusobacterium necrophorum. , 2012, The Lancet. Infectious diseases.

[13]  Chien-Chang Yang,et al.  Fusobacterium bacteremia: clinical significance and outcomes. , 2009, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[14]  S. Strasberg Clinical practice. Acute calculous cholecystitis. , 2008, The New England journal of medicine.

[15]  T. Riordan Human Infection with Fusobacterium necrophorum (Necrobacillosis), with a Focus on Lemierre's Syndrome , 2007, Clinical Microbiology Reviews.

[16]  I. Beckingham,et al.  Acute cholecystitis , 2002, BMJ : British Medical Journal.

[17]  E. Martín-Pérez,et al.  Perforated emphysematous cholecystitis and Streptococcus bovis. , 2019, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[18]  J. Dillman,et al.  Cross-sectional imaging of acute and chronic gallbladder inflammatory disease. , 2009, AJR. American journal of roentgenology.

[19]  James G. Chandler,et al.  A comparative appraisal of emphysematous cholecystitis. , 1975, American journal of surgery.